Intracardiac CD133+ Cells in Patients With No-option Resistant Angina (RegentVsel)
This study is currently recruiting participants.
Verified April 2016 by Wojciech Wojakowski MD, PhD, Medical University of Silesia
Medical University of Silesia
Information provided by (Responsible Party):
Wojciech Wojakowski MD, PhD, Medical University of Silesia
First received: August 6, 2012
Last updated: April 15, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is currently recruiting participants.|
|Estimated Study Completion Date:||December 2016|
|Estimated Primary Completion Date:||December 2016 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Wojakowski W, Jadczyk T, Michalewska-Włudarczyk A, Parma Z, Markiewicz M, Rychlik W, Kostkiewicz M, Gruszczyńska K, Błach A, Dzier Zak-Mietła M, Wańha W, Ciosek J, Ochała B, Rzeszutko Ł, Cybulski W, Partyka Ł, Zasada W, Włudarczyk W, Dworowy S, Kuczmik W, Smolka G, Pawłowski T, Ochała A, Tendera M. Effects of Transendocardial Delivery of Bone Marrow-Derived CD133(+) Cells on Left Ventricle Perfusion and Function in Patients With Refractory Angina: Final Results of Randomized, Double-Blinded, Placebo-Controlled REGENT-VSEL Trial. Circ Res. 2017 Feb 17;120(4):670-680. doi: 10.1161/CIRCRESAHA.116.309009. Epub 2016 Nov 30.